Молекулярные механизмы патогенеза розацеа

Литература:
1. Потекаев Н. Н., Янсен Т., Флайг М. Гемангиома и роза-цеа // Вестн. дерматол. и венерол. 2000. № 2. С. 32-34; 2. Темников В. Е. Особенности иммунного статуса при розовых угрях // Иммунология в дерматовенерологии. 1999. С. 86-88; 3. Laser and light therapies for acne rosacea / K. L. Butterwick [et al.] // J. Drugs Dermatol. 2006. Vol. 5, № 3. pt. 35. P. 9; 4. Skin immune sentinels in health and disease / F. O. Nestle, Di Meglio P., J.Z. Qin, B.J. Nickoloff// Nat. Rev. Immunol. 2009. Pt. 9. P. 679-691; 5. Сницаренко О. В. Вазоактивные полипептиды при ро-зацеа // Вестн. дерматол. и венерол. 1995. № 9. С. 42-44; 6. Objective and Quantitative Improvement of Rosacea-Associated Erythema after IPL Treatment / K.A. Mark, R.M. Sparacio, A. Voigt [et al.] // Dermatol. Surg. 2003. Vol. 29. P. 600-604; 7. Самцов А. В. Учебно-исследовательская лаборатория клинической дерматогистопатологии на основе систем искусственного интеллекта // Вестн. Рос. воен.-мед. акад. 2000. № 1. С. 94-97; 8. Papules of the face / N. Ghariani, M. Kourda, M. Denguczli [et al.] //Ann. Dermatol. Venereol. 2002. Vol. 129, № 10, pt. 1. P. 1181-1182; 9. Yamasaki K., Gallo R.L. The molecular pathology of rosacea / // Journal of Dermatological Science. 2009. Vol. 55. P. 77-81; 10. Природная устойчивость бактерий к факторам врожденной иммунной системы, обусловленная бактериальными протеазами / Ю.А. Тюрин, И.Г. Мустафин, PC. Фасса-хов // Практическая медицина. Казань. 2010. № 1. С. 7-13; 11. Toll-like receptors / К. Takeda, Т. Kaisho, S. Akira // Ann. Rev. Immunol. 2003. № 21. P. 335-376; 12. Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin / K. Yamasaki, J. Schauber, A. Coda [et al.] // FASEB J. 2006. № 20. P. 2068-2080; 13. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea/K. Yamasaki, D.A. Nardo, A. Bardan [et al.] // Nat. Med. 2007. № 13. P. 975-980; 14. Cathelicidin LL-37 induces the generation of reactive oxygen species and release of human alpha-defensins from neutrophils / Y Zheng, F. Niyonsaba, H. Ushio [et al.] // Br.J. Dermatol. 2007. № 157. P. 1124-1131; 15. Host defense peptide LL-37, in synergy with inflammatory mediator IL-1 beta, augments immune responses by multiple pathways / J. Yu, N. Mookherjee, K. Wee [et al.] // J. Immunol. 2007. № 179. P. 7684-7691; 16. IL-17A enhances vitamin D3-induced expression of cathelicidin antimicrobial peptide in human keratinocytes / M. Peric, S. Koglin, S. M. Kim [et al.] // J. Immunol. 2008. № 181. P. 8504-8512; 17. Keratinocyte production of cathelicidin provides direct activity against bacterial skin pathogens/ M.H. Braff, M. Zaiou, J. Fierer[etal.]//Infect. Immun. 2005. №73. P. 6771-6781; 18. Angiogenesis in cutaneous disease: part II /V Laquer, V Hoang, A. Nguyen, K.M. Kelly//J.Am. Acad. Dermatol. 2009. Vol. 61, № 6. P. 945-960; 19. Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism / J. Schauber, R.A. Dorschner, A. B. Coda [et al.] // J. Clin. Invest.2007. №117. P. 803-811; 20. Antimicrobial peptides: key components of the innate immune system / M. Pasupuleti, A. Schmidtchen, M. Malmsten // Crit. Rev. Biotechnol. 2011. [Epub ahead of print]; 21. A New Perspective on Rosacea: The Role of Innate Immunity / L. E. Maier, K. Yamasaki, R. L. Gallo // US Dermatol. Rev. 2007. P. 19-21; 22. UV-B-triggered induction of vitamin D3 metabolism differentially affects antimicrobial peptide expression in keratinocytes / M. Peric, B. Lehmann, G. Vashina [et al.] // J. Allergy. Clin. Immunol. 2010. № 125. P. 746-749; 23. The potential role of microorganisms in the development of rosacea / E. Lazaridou, О Giannopoulou, О Fotiadou [et al.] // J. Dtsch. Dermatol. Ges. 2011. № 9. P. 21-25; 24. Chosidow O. Epidemiology of rosacea: updated data // Ann. Dermatol. Venereol. 2011. Vol. 138 (Suppl. 2). P. 124-128; 25. Impact of vitamin D3 on cutaneous immunity and antimicrobial peptide expression /A.S. Antal, Y. Dombrowski, S. Koglin, [et al.] // J. Dermatoendocrinol. 2011. № 3. P. 18-22; 26. Jones D.A. Rosacea, reactive oxygen species, and azelaic acid // J. Clin. Aesthetic Derm. 2009. Vol. 2, № 1. P. 26-30; 27. Schauber J., Gallo R. L. The vitamin D pathway: a new target for control of the skin»s immune response // Exp. Dermatol. 2008. №17. P. 633-639; 28. Oxidative stress and ferritin expression in the skin of patients with rosacea / VS. Tisma, A. Basta-Juzbasic, M. Jaganjac [et al.] // J.Am. Acad. Dermatol. 2009. Vol. 60, № 2. P. 270-276; 29. Smith J.R., Lanier V B. Expression of VEGF and its receptors in rosacea // Br.J. Ophthalmol. 2007. № 91. P. 226-229; 30. Cuevas P., Arrazola J.M. Therapeutic response of rosacea to dobesilate // Eur.J. Med. Res. 2005. Vol. 10, № 10. P 454-456. 31. Folkman J., Klagsburn M. Angiogenic factors // Science. 1987. Vol. 235. P. 442-447; 32. Lymphangiogenesis and angiogenesis in non-phymatous rosacea / A.H. Gomaa, M. Yaar, M.M. Eyada, J. Bhawan // J. Cutan. Pathol. 2007. № 34. P. 748-753; 33. Functional changes induced by chronic UVA irritation to cultured human dermal fibroblasts / E. Naru, T. Suzuki, M. Moriyama [et al.] // Br.J. Dermatol. 2005. Vol. 153 (Suppl. 2). P. 6-12; 34. Myeloid Differentiation Factor 88 Regulates Basal and UV-lnduced Expressions of IL-6 and MMP-1 in Human Epidermal Keratinocytes / Y Lee, S. Kim, M.H. Shin, К H. Kim [et al.] // J. Invest. Dermatol. 2009. № 129. P. 460-467; 35. A study of the pathogenesis of Rosacea: how angiogenesis and mast cells may participate in a complex multifactorial process / К. Aroni, E. Tsagroni, N. Kavantzas [et al.] //Arch. Dermatol. Res. 2008. Vol. 300, № 3. P. 125-131; 36. Reactive oxygen species in tumor necrosis factor-alpha-activated primary human keratinocytes: implications for psoriasis and inflammatory skin disease / С N. Young, J.I. Koepke, L.J. Terlecky [et al.]// J. Invest. Dermatol. 2008. № 128. P. 2606-2614; 37. Schauber J., Gallo R.L. Expanding the roles of antimicrobial peptides in skin: alarming and arming keratinocytes //J. Invest. Dermatol. 2007. № 127. P. 510-512.